目的 :观察葛根素对II型糖尿病病人血小板聚集功能及微量清蛋白尿的影响。方法 :对 46例II型糖尿病伴微量清蛋白尿病人 ,2 3例在常规治疗糖尿病 (甲苯磺丁脲或格列齐特口服 )基础上加用葛根素 30 0～ 40 0mg加入 0 .9%氯化钠注射液 5 0 0mL中静脉滴注 ,qd× 13～ 15d。另 2 3例病人单用常规治疗 13～ 15d为对照组。 2组均于治疗前后检测血小板聚集率、血浆凝血烷B2 (TXB2 ) ,血浆α颗粒膜蛋白_14 0 (GMP_14 0 )、微量清蛋白尿的变化。结果 :葛根素组血小板聚集率下降 ( 48± 5 ) % ,TXB2水平下降 ( 116± 87)ng/L ,尿微量清蛋白下降 ( 138± 2 1)mg/L ;而常规治疗组依次为 ( - 1± 11) % ,( 1± 62 )ng/L及 ( 2± 35 )mg/L ;2组组间比较 ,差别均有非常显著意义 (P <0 .0 1)。反映血小板活化的GMP_14 0 ,2组均无显著改变。结论 :葛根素有改善血小板功能、减少糖尿病微量清蛋白尿的作用 Objective: To observe the effects of puerarin on platelet aggregation and microalbuminuria in type 2 diabetic patients. Methods: Forty-six patients with type II diabetes mellitus and microalbuminuria were enrolled. Twenty-three of them were given Puerarin 30 0 ~ 40 0 ​​mg on the basis of conventional treatment of diabetes mellitus (tolbutamide or gliclazide orally) with 0.9% Sodium chloride injection 500mL intravenous infusion, qd × 13 ~ 15d. The other 23 patients with conventional treatment alone 13 ~ 15d as control group. The changes of platelet aggregation rate, plasma TXB2, plasma GMP-140, and albuminuria in both groups were measured before and after treatment. Results: The platelet aggregation rate was decreased (48 ± 5)% in puerarin group, the TXB2 level was decreased (116 ± 87) ng / L and the urine microalbumin was decreased (138 ± 21) mg / - 1 ± 11)%, (1 ± 62) ng / L and (2 ± 35) mg / L, respectively. There was significant difference between the two groups (P <0.01). There was no significant change in GMP_14 0 and 2 groups reflecting platelet activation. Conclusion: Puerarin has the effect of improving platelet function and reducing the microalbuminuria in diabetic patients